A judge has ruled against investor Alcon Research on the matter of blocking investee Aurion Biotech from debuting on the ...

Imperative Care has received a green light from the FDA for its large-bore catheter to help remove stroke-causing blood clots ...

Philips is parting ways with its worldwide emergency care business, including its catalog of automated external ...

Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...

Having shown last week that its opioid alternative can reduce post-surgery pain, Tris Pharma is back with another slice of ...

After 20 years of building radioisotope expertise as a manufacturer and supplier, German firm ITM Isotope Technologies is ...

Two months after launching Pep2Tango Therapeutics, VC firm Versant Ventures is unveiling another obesity-focused biotech in ...

Takeda is taking back the home license for a phase 3-ready depression drug as part of an amendment to its multi-asset ...

Transforming life sciences with AI, powered by Salesforce Life Sciences Cloud | Drug development and commercialization leads ...

Demand slipped for several large contract research organizations last year, and a new report from William Blair analysts suggests these firms should brace for a similar R&D landscape in 2025.

Leap Therapeutics has come crashing down to earth. The biotech axed plans to advance into phase 3 in gastric cancer on the basis of midstage data, sending its stock down 60% to below $1, but it is ...

Just days after President Trump imposed broad restrictions on communications, meetings, travel and public appearances at the ...